We believe that patients with severe combined immunodeficiency and any form of mild local changes at the BCG injection site should be given single or double anti-TB therapy, which should be continued until complete immunologic reconstitution occurs after bone marrow transplant. Severe local BCG infection with regional lymph node involvement needs at least triple anti-TB therapy followed by long-term prophylaxis. Disseminated BCG infection needs anti-TB therapy, including ≥4 anti-TB drugs, until the patient fully recovers.

Acknowledgments

E.A.B. thanks Peter Folb, Dina Pfeiffer, and Adwoa Bentsi-Enchill for encouragement in writing this article.

The investigation was supported by grant EURO-POLICY-primary immunodeficiency SP23-CT-2005-006411 and national project no. PBZ-KBN-119/PO5/04.

Ewa Anna Bernatowska,* Beata Wolska-Kusnierz,* Malgorzata Pac,* Magdalena Kurenko-Deptuch,* Zofia Zwolska,† Jean-Laurent Casanova,‡ Barbara Piatosa,* Jacques van Dongen,§ Kazimierz Roszkowski,† Bozena Mikoluc,¶ Maja Klaudel-Dreszler,* and Anna Liberek¶

*Children’s Memorial Health Institute, Warsaw, Poland; †National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland; ‡University Rene Descartes, Paris, France; §University Medical Center, Rotterdam, the Netherlands; and ¶Medical University of Białystok, Białystok, Poland

References


Address for correspondence: Ewa Anna Bernatowska, Children’s Memorial Health Institute, Department of Immunology, Av. Dzieci Polskich, 20 Warsaw, 04-730 Mazovia, Poland; email: bernatowskae@yahoo.com

Clindamycin-resistant Streptococcus pneumoniae

To the Editor: Antimicrobial medications classified as macrolides (e.g., erythromycin) and lincosamides (e.g., clindamycin) show strong activity against streptococci and are commonly used to treat community-acquired infections caused by Streptococcus pneumoniae. Moreover, these drugs are the recommended alternatives for patients who cannot tolerate β-lactams.

Two main macrolide-resistant S. pneumoniae phenotypes have been reported (1). The first has a high level of resistance to all macrolides, lincosamides, ketolides, and streptogramins B due to ribosomal dimethylation, 23S rRNA mutations, or ribosomal protein mutations (MLS₁, MLS₂, ML, MKS₁, and K phenotypes). The second is characterized by a low-level resistance (e.g., MIC 2–4 mg/L) to only 14- and 15-member ring macrolides (M phenotype) because of mef gene–mediated active drug efflux mechanism.

In January 2005, an erythromycin-susceptible but clindamycin-resistant pneumococcal strain was obtained from a conjunctival swab of a 10-month-old female outpatient attending the daycare center of the Clinic and Laboratory of Infectious Diseases, Siena University, Siena, Italy. To our knowledge, such a phenotype has not been reported in the international literature for S. pneumoniae, although a similar phenotype of S. agalactiae was described by Malbruny et al. (2).

The S. pneumoniae isolate was identified by standard procedures (3) and confirmed by PCR for the common capsule gene cpsA (4). Serotype-testing, performed by Quellung reaction, showed a 35F serotype. Susceptibility testing was carried out by disk diffusion and confirmed with E-test according to Clinical and Laboratory
genes with primers described by Canu et al. (10). Although these findings are preliminary and the molecular basis for resistance is the subject of ongoing investigation, the identification of this S. pneumoniae phenotype may affect clinical management of pneumococcal infections, especially in the treatment of patients intolerant of β-lactams.

Acknowledgments

We thank Elisabetta Mantengoli for useful suggestions on gene sequencing and Sanofi Aventis for providing telithromycin.

Strain serotyping was performed at Streptococcal Reference Unit of Respiratory and Systemic Infection Laboratory, Centre for Infections, Health Protection Agency, London, UK.

Francesca Montagnani,*1 Alessandra Zanchi,*1 Lucia Stolzluoi,* Leonardo Croci,* and Carla Cellesi*

*Clinica e Laboratorio di Malattie Infettive, Università degli Studi di Siena, Italy

References


Address for correspondence: Francesca Montagnani, Clinica e Laboratorio di Malattie Infettive, Dipartimento di Biologia Molecolare, Università di Siena, Ospedale Le Scotte, Piano 0 lotto IV, Viale Bracci, 16, 53100 Siena, Italy; email: montagnani2@unisi.it

*Contributed equally to this work.